|
Bisphosphonate is a therapeutic agent used for treating osteoporosis patients for more than a decade, with a proven efficacy to increase bone mass and decrease the occurrence of bone fracture. Through 90-day bed rest research on Earth, we confirmed that this agent has a preventive effect in the loss of bone mass. Based on these results, as well as studies conducted by others, JAXA and NASA decided to collaborate on a space biomedical experiment to prevent bone loss during space flight. Dr. Leblanc, USRA and Dr. Matsumoto, Tokushima University are the two principal investigators of this study. JAXA and NASA crew members are participating in this study by taking this agent once a week while in space. Our study is still ongoing, however, early results suggest that astronauts can reduce the risk of bone loss and renal stone risk by proper intake of appropriate nutrients, such as calcium and vitamin D, an effective exercise program, and taking minimal amounts of medication.
|